Media coverage about pSivida (NASDAQ:PSDV) has trended somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. pSivida earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.1025538032401 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern’s scoring:
pSivida (NASDAQ PSDV) opened at $1.05 on Tuesday. The firm has a market capitalization of $47.52, a price-to-earnings ratio of -2.28 and a beta of 1.26. pSivida has a 12 month low of $1.02 and a 12 month high of $2.45.
pSivida (NASDAQ:PSDV) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.74 million. pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%. equities analysts expect that pSivida will post -0.59 earnings per share for the current year.
PSDV has been the topic of a number of research reports. HC Wainwright set a $5.00 target price on pSivida and gave the stock a “buy” rating in a research report on Wednesday, October 11th. ValuEngine lowered pSivida from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Northland Securities reissued a “buy” rating and issued a $10.00 price target on shares of pSivida in a research report on Monday, December 11th. Laidlaw began coverage on pSivida in a research report on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price target for the company. Finally, B. Riley set a $5.00 price target on pSivida and gave the company a “buy” rating in a research report on Friday, December 15th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $7.57.
TRADEMARK VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/06/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-psivida-psdv-stock-price.html.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.